- Home
- Publications
- Publication Search
- Publication Details
Title
Tivantinib for the treatment of hepatocellular carcinoma
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 18, Issue 7, Pages 727-733
Publisher
Informa UK Limited
Online
2017-04-18
DOI
10.1080/14656566.2017.1316376
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma
- (2017) Nicola Personeni et al. Oncotarget
- Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma
- (2016) Jian Zheng et al. ANNALS OF SURGICAL ONCOLOGY
- A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors
- (2016) Christos E. Kyriakopoulos et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors
- (2015) Takuji Okusaka et al. CANCER SCIENCE
- Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.
- (2015) Anthony B. El-Khoueiry et al. JOURNAL OF CLINICAL ONCOLOGY
- Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
- (2015) Qingfeng Xiang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
- (2014) S. Pant et al. ANNALS OF ONCOLOGY
- Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
- (2014) Q. Xiang et al. CLINICAL CANCER RESEARCH
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
- (2014) Igor Puzanov et al. INVESTIGATIONAL NEW DRUGS
- Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines
- (2014) Antonio Calles et al. Molecular Oncology
- The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors
- (2013) N. Yamamoto et al. ANNALS OF ONCOLOGY
- A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
- (2013) A Santoro et al. BRITISH JOURNAL OF CANCER
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- (2013) R. Katayama et al. CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET--Letter
- (2013) L. Rimassa et al. CLINICAL CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
- (2012) Jonathan W. Goldman et al. CANCER
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
- (2011) Yunwei Han et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
- (2011) L. S. Rosen et al. CLINICAL CANCER RESEARCH
- Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197
- (2011) Sudharshan Eathiraj et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
- (2010) Judith Ertle et al. INTERNATIONAL JOURNAL OF CANCER
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
- (2010) N. Munshi et al. MOLECULAR CANCER THERAPEUTICS
- Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
- (2009) Kohei Shitara et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Signaling networks assembled by oncogenic EGFR and c-Met
- (2008) A. Guo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now